Search results

• 2C-B
  experienced by users of 2C-B. Research also suggests that 2C-B increases dopamine levels in the brains of rats which may contribute to its psychoactivity
  36 KB (4,745 words) - 16:35, 7 April 2024
• Methylphenidate
  primarily acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It is most active at modulating levels of dopamine and, to a lesser extent, norepinephrine
  31 KB (4,254 words) - 15:15, 6 May 2024
• Opioids
  receptors with serotonin, dopamine, and norepinephrine. Activation of mu receptors allows for the disinhibition of serotonin and dopamine neurons by blocking
  19 KB (2,797 words) - 02:47, 12 May 2024
• Cocaine
  and thus dopamine accumulates in the synaptic cleft. The increased concentration of dopamine in the synapse activates post-synaptic dopamine receptors
  47 KB (6,322 words) - 08:08, 3 May 2024
• Mephedrone
  reinforcing potential of mephedrone. Dopamine and serotonin were collected using microdialysis, and increases in dopamine and serotonin were measured. Mephedrone
  29 KB (3,963 words) - 14:23, 16 April 2024
• 2-FMA
  acts as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine and dopamine in the brain
  17 KB (2,934 words) - 17:24, 18 January 2024
• 2-FA
  primarily as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine and dopamine neurotransmitters
  17 KB (3,024 words) - 17:25, 18 January 2024
• MDA
  with MDMA, MDA is thought to act primarily as a serotonin-norepinephrine-dopamine reuptake inhibitor and releasing agent.[citation needed] However, MDA is
  31 KB (4,379 words) - 12:23, 6 May 2024
• Adrenaline
  monoamine chain can be found in many neurotransmitters, including histamine, dopamine, serotonin and noradrenaline. It is also found in many psychoactive substances
  5 KB (628 words) - 23:12, 21 April 2024
• Lisdexamfetamine
  such as dopamine, serotonin and noradrenaline. The agonism of this set of receptors results in the release of increased concentrations of dopamine, serotonin
  23 KB (3,617 words) - 09:16, 17 April 2024
• Modafinil
  not reduced by the dopamine receptor antagonist haloperidol in rats. In addition, alpha-methyl-p-tyrosine, an inhibitor of dopamine synthesis, blocks the
  19 KB (3,104 words) - 11:29, 16 April 2024
• Isopropylphenidate
  widely-prescribed ADHD medication methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI). Isopropylphenidate has been investigated for
  19 KB (2,684 words) - 18:04, 30 July 2022
• 3-FPM
  1950s. It produces its activity by increasing the levels of serotonin, dopamine, and norepinephrine in the brain. The synthesis and pharmacology of 3-FPM
  15 KB (2,265 words) - 06:42, 8 September 2023
• 3-MMC
  of mephedrone (4-MMC). The mechanism of action is not fully studied, but dopamine and serotonin and norepinephrine releasing activity is known to be involved
  18 KB (2,590 words) - 21:20, 30 April 2024
• 4F-MPH
  thought to act primarily as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters
  16 KB (2,465 words) - 15:45, 9 May 2024
• ΑMT
  releasing agent of the main three monoamines; serotonin, norepinephrine, and dopamine, and as a non-selective serotonin receptor agonist. αMT's psychedelic effects
  25 KB (2,825 words) - 16:14, 28 November 2022
• 3-FEA
  potent dopamine releaser. This indicates that 3-FEA effectively increases the levels of all the three major monoamine neurotransmitters dopamine, norepinephrine
  19 KB (3,317 words) - 15:23, 30 July 2022
• GHB
  profile of GHB. GHB's effect on dopamine release is biphasic. This means that while low concentrations stimulate dopamine release via the GHB receptor, higher
  35 KB (4,460 words) - 13:32, 16 April 2024
• 3-FA
  the notable exception of 4-FA), it most likely acts primarily as both a dopamine and norepinephrine releasing agent, with modest selectivity for serotonin
  15 KB (2,726 words) - 11:39, 17 February 2024
• MDAI
  highly selective serotonin releasing agent (SSRA) with neglible effects on dopamine and norepinephrine. MDAI was developed by the American medicinal chemist
  17 KB (2,560 words) - 07:40, 12 October 2023

View (previous 20 | next 20) (20 | 50 | 100 | 250 | 500)